EVOKE PHARMA INC (EVOK)
US30049G2030 - Common Stock
Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive Officer
SOLANA BEACH, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on...
EVOK Stock Earnings: Evoke Pharma Misses EPS, Beats Revenue for Q4 2023
EVOK stock results show that Evoke Pharma missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
EVOK Stock Earnings: Evoke Pharma Misses EPS, Beats Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Evoke Pharma (NASDAQ:EVOK) just reported results for the fourth quarter of 2023...
Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results
Fiscal year 2023 net product sales from prescriptions totaled approximately $5.2M, a 107% increase from 2022 Company projects $14M in net revenue for...
Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024
SOLANA BEACH, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for...
Evoke Pharma Announces Closing of $7.5 Million Public Offering
Potential for Additional $22.5 Million in the Event of Exercise of Common Warrants in Full...
Evoke Pharma down 28%, prices $30M offering (NASDAQ:EVOK)
Evoke Pharma announces pricing of underwritten public offering, led by Nantahala Capital Management, for gross proceeds of up to $30M.
Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million
SOLANA BEACH, Calif., Feb. 09, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on...
Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent
GIMOTI now holds four listed patents with coverage through 2029...
United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI
The Company Will Submit for FDA Orange-Book Listing in the Near Term...
Evoke Pharma files to sell common stock and warrants (NASDAQ:EVOK)
Evoke Pharma files prospectus for the sale of common stock and warrants, clarifying it is not an offer to sell these securities.
Evoke Pharma Reports Third Quarter 2023 Financial Results
38% Revenue Increase Compared to Q2 2023; 88% Increase Year-Over-Year Seventh Straight Prescription Fill Increase Since Q1 2022 21% Increase Compared to...
Evoke Pharma & EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide Presented at the American College of Gastroenterology 2023
Reduction in emergency department visits, hospitalizations and office visits caused diabetic gastroparesis patients and insurers to save over $15,000 for...
7 Under-the-Radar Growth Stocks Ready to Make a Splash
By being involved in some of the most creative industries, these growth stocks help you capitalize on emerging trends and technologies.
Evoke Pharma’s Abstract Entitled “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients” to Be Presented at The American College of Gastroenterology (ACG) 2023
Selected for a Distinguished Oral Plenary Presentation...
Evoke Pharma Receives Notice of Allowance from USPTO for GIMOTI®
SOLANA BEACH, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on...
Evoke Pharma Reports Second Quarter 2023 Financial Results
40% revenue growth compared to Q1 2023 34% increase in prescription fills compared to Q1 2023 Presented industry-leading real-world healthcare...
Evoke Pharma and EVERSANA Announce Abstract Acceptance at 2023 American Neurogastroenterology and Motility Society (ANMS) Meeting
Real-world study that explored the healthcare utilization resource utilization among patients receiving GIMOTI with and without prior treatment with oral...
Evoke Pharma and EVERSANA Announce Abstract Selection for Plenary Oral Presentation at The American College of Gastroenterology (ACG) 2023 Annual Meeting
“Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients”...
Evoke Pharma to Host First Key Opinion Leader Webinar on Healthcare Resource Utilization Data Related to Gastroparesis and its Treatment
Study between nasal and oral metoclopramide selected by Digestive Disease Week (DDW) 2023 faculty for plenary presentation...